India's Lupin Strengthens Its Brand Presence With Oscient Pharma's Antara
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - For Lupin - the fast emerging Indian generic drug maker - the switch from pure generic drugs in the U.S. to a patented and branded play is happening faster than many analysts expected. Lupin made an audacious $38.61 million bid for bankruptcy-threatened Oscient Pharma's top cardiovascular drug Antara (fenofibrate), and finally clinched the deal while outpacing at least three other generic rivals